<?xml version="1.0" encoding="UTF-8"?>
<ref id="CR49">
 <label>49.</label>
 <element-citation publication-type="journal">
  <person-group person-group-type="author">
   <name>
    <surname>Misra</surname>
    <given-names>RN</given-names>
   </name>
   <name>
    <surname>Xiao</surname>
    <given-names>HY</given-names>
   </name>
   <name>
    <surname>Kim</surname>
    <given-names>KS</given-names>
   </name>
   <name>
    <surname>Lu</surname>
    <given-names>S</given-names>
   </name>
   <name>
    <surname>Han</surname>
    <given-names>WC</given-names>
   </name>
   <name>
    <surname>Barbosa</surname>
    <given-names>SA</given-names>
   </name>
   <etal/>
  </person-group>
  <article-title>N-(cycloalkylamino) acyl-2-aminothiazole inhibitors of cyclin-dependent kinase 2. N-[5-[[[5-(1, 1-dimethylethyl)-2-oxazolyl] methyl] thio]-2-thiazolyl]-4-piperidinecarboxamide (BMS-387032), a highly efficacious and selective antitumor agent</article-title>
  <source>J Medicinal Chem</source>
  <year>2004</year>
  <volume>47</volume>
  <fpage>1719</fpage>
  <lpage>28</lpage>
  <pub-id pub-id-type="doi">10.1021/jm0305568</pub-id>
 </element-citation>
</ref>
